|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Segment
Analysis
Our business is organised into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities primarily in
Alzheimer’s disease, Parkinson’s disease, multiple
sclerosis, Crohn’s disease, severe chronic pain and
infectious diseases. EDT is an established, profitable specialty
pharmaceutical business unit of Elan. For additional information
on our current operations, please refer to the “Operating
Review” on pages 17 to 50.
This excerpt taken from the ELN 20-F filed Feb 26, 2009. SEGMENT
ANALYSIS
Our business is organized into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities primarily in
Alzheimer’s disease, Parkinson’s disease, MS, CD,
severe chronic pain and infectious diseases. EDT is an
established, profitable specialty pharmaceutical business unit
of Elan. For additional information on our current operations,
refer to Item 4.B. “Business Overview.”
Table of Contents
This excerpt taken from the ELN 6-K filed Mar 31, 2008. Segment
Analysis
Our business is organised into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities primarily in
Alzheimer’s disease, Parkinson’s disease, multiple
sclerosis, Crohn’s disease, severe chronic pain and
infectious diseases. EDT is an established, profitable and
growing specialty pharmaceutical business unit of Elan. For
nearly 40 years, EDT has been applying its skills and
knowledge to enhance the performance of dozens of drugs that
have been marketed worldwide.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. SEGMENT
ANALYSIS
Our business is organized into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities primarily in
Alzheimer’s disease, Parkinson’s disease, multiple
sclerosis, Crohn’s disease, severe chronic pain and
infectious diseases. EDT is an established, profitable and
growing specialty pharmaceutical business unit of Elan. For
nearly 40 years, EDT has been applying its skills and
knowledge to enhance the performance of dozens of drugs that
have been marketed worldwide. For additional information on our
current operations, please refer to Item 4.B.
“Business Overview.”
This excerpt taken from the ELN 6-K filed Mar 30, 2007. Segment
Analysis
Segment information is presented in respect of our two business
units: Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities and includes our
activities in the areas of autoimmune diseases,
neurodegenerative diseases, and our specialty business group.
EDT focuses on product development,
scale-up and
manufacturing to address drug optimisation challenges of the
pharmaceutical industry.
Our total revenue in 2006 of $497.3 million (2005:
$426.7 million) was comprised of revenue from
Biopharmaceuticals and EDT of $249.9 million (2005:
$204.3 million) and $247.4 million (2005:
$222.4 million), respectively. Our operating loss of
$286.1 million (2005: $453.8 million) was primarily
comprised of the segment losses incurred by Biopharmaceuticals
of $315.2 million (2005: $445.1 million), offset by
segment income incurred by EDT of $28.8 million (2005:
$8.0 million loss).
Biopharmaceuticals’ revenue increased 22% to
$249.9 million in 2006 from $204.3 million in 2005,
primarily due to higher sales of Maxipime, Azactam
and Prialt. Biopharmaceuticals’ operating loss
decreased 29% to $315.2 million from $445.1 million in
2005 principally due to increased revenues and decreased R&D
and SG&A expenses.
EDT’s revenue increased 11% to $247.4 million in 2006
from $222.4 million in 2005 as a result of increased
manufacturing revenue and royalties (primarily Tricor and
Skelaxin). EDT’s operating income increased to
$28.8 million in 2006 from $8.0 million loss in 2005,
primarily due to increased revenues and also due to an
arbitration award of $49.8 million in our favour and
against King in 2006.
This excerpt taken from the ELN 20-F filed Feb 28, 2007. SEGMENT
ANALYSIS
Our business is organized into two segments: Biopharmaceuticals
and EDT. Biopharmaceuticals engages in research, development and
commercial activities and includes our activities in the areas
of autoimmune diseases, neurodegenerative diseases, and our
specialty business group. EDT focuses on product development,
scale-up and
manufacturing to address drug optimization challenges of the
pharmaceutical industry.
This excerpt taken from the ELN 6-K filed Mar 31, 2006. Segment Analysis
Segment information is presented in respect of our two business
units: Biopharmaceuticals and EDT, formerly Global Services and
Operations. Biopharmaceuticals engages in research, development
and commercial activities and includes our activities in the
areas of autoimmune diseases, neurodegenerative diseases, and
our specialty business group. EDT focuses on product
development, scale-up
and manufacturing to address drug optimisation challenges of the
pharmaceutical industry.
Our total revenue in 2005 of $426.7 million (2004:
$367.0 million) was comprised of revenue from
Biopharmaceuticals and EDT of $225.9 million (2004:
$201.1 million) and $200.8 million (2004:
$165.9 million), respectively. Our operating loss of
$453.8 million (2004: $431.4 million) was primarily
comprised of the segment losses incurred by Biopharmaceuticals
and EDT of $402.2 million (2004: $349.2 million) and
$14.2 million (2004: $22.7 million), respectively.
Biopharmaceuticals’ revenue increased 12% to
$225.9 million in 2005 from $201.1 million in 2004,
primarily due to higher sales of Maxipime and
Azactam, and initial sales of Prialt, offset by
reduced contract revenue principally due to the receipt of
$14.0 million of Tysabri-related milestones in 2004.
Biopharmaceuticals’ operating loss increased 15% to
$402.2 million from $349.2 million in 2004 principally
due to the additional costs incurred in relation to Tysabri
during 2005.
EDT’s revenue increased 21% to $200.8 million in 2005
from $165.9 million in 2004 as a result of increased
manufacturing revenue and royalties (primarily Tricor), offset
by reduced contract revenue. EDT’s operating loss decreased
to $14.2 million in 2005 from $22.7 million in 2004,
primarily due to increased revenues.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. SEGMENT
ANALYSIS
Our business is organized into two segments: Biopharmaceuticals
and EDT (formerly known as Global Services and Operations).
Biopharmaceuticals engages in research, development and
commercial activities and includes our activities in the areas
of autoimmune diseases, neurodegenerative diseases, and our
specialty business group. EDT focuses on product development,
scale-up and
manufacturing to address drug optimization challenges of the
pharmaceutical industry.
Our total revenue of $490.3 million in 2005 (2004:
$481.7 million; 2003: $685.6 million) was comprised of
revenue from Biopharmaceuticals of $250.8 million (2004:
$275.1 million; 2003: $479.7 million) and EDT of
$239.5 million (2004: $206.6 million; 2003:
$205.9 million). Our total operating loss of
$198.5 million in 2005 (2004: $302.1 million; 2003:
$360.5 million) was comprised primarily of operating losses
incurred by Biopharmaceuticals of $225.4 million (2004:
$253.2 million; 2003: $318.1 million), partially
offset by operating income from EDT of $27.6 million (2004:
$14.2 million; 2003: $5.7 million).
Biopharmaceuticals’ revenue decreased 9% to
$250.8 million in 2005 from $275.1 million in 2004 and
48% from $479.7 million in 2003. The decrease is primarily
due to the decrease in revenue from divested products, offset by
increased sales of Maxipime and Azactam.
Biopharmaceuticals’ operating loss decreased 11% to $225.4
from $253.2 million in 2004 and 29% from
$318.1 million in 2003. The decrease in the operating loss
was principally due to the increase in the gain on sale of
businesses, offset by a decrease in revenues.
Biopharmaceuticals’ net gain on sale of businesses
increased from $41.2 million in 2004 to $103.1 million
in 2005, primarily related to the gain on sale of Zonegran and
our European business, principally due to the receipt of
contingent considerations in 2005. Biopharmaceuticals’
other significant net charges increased from $0.2 million
in 2004 to $5.6 million in 2005, primarily due to
severance, relocation, and exit costs incurred relating to the
realignment of our resources to meet our current business
structure. In 2003, Biopharmaceuticals incurred net significant
other charges of $343.7 million, which primarily related to
the purchase of royalty rights from Pharma Marketing.
EDT revenue increased to $239.5 million in 2005 from
$206.6 million in 2004 and increased 16% from
$205.9 million in 2003. The increase from 2004 was
primarily due to increased sales by third parties that
incorporate Elan’s technologies. EDT operating income
increased to $27.6 million in 2005 from $14.2 million
in 2004, primarily due to the increase in revenues. EDT gain on
sale of businesses decreased from a $3.0 million gain in
2004 to a $0.3 million gain in 2005. EDT did not incur
material other significant net charges in either 2005 or 2004.
In 2003, EDT incurred net significant other charges of
$13.9 million, which related primarily to asset impairments.
This excerpt taken from the ELN 6-K filed Apr 11, 2005. Segment Analysis In 2002, we suffered a number of setbacks in rapid succession, including the cessation of dosing in a Phase IIA clinical trial of AN-1792, an experimental immunotherapeutic that was under development for the treatment of Alzheimer’s disease, and the announcement of a profit warning and an investigation by the SEC. These disappointments ultimately led to a loss of confidence in us. To address these issues, we began a recovery plan in July 2002 to restructure our business in order to meet our financial commitments. In February 2004, we announced the formal completion of our recovery plan. The recovery plan, which was announced on 31 July 2002, involved the restructuring of our businesses, assets and balance sheet; and resulted in gross consideration of $2.1 billion, ahead of the target of $1.5 billion. With the completion of the recovery plan, the operations of Core Elan and Elan Enterprises were reorganised into two business units: Biopharmaceuticals and GS&O. In this reorganisation, our Core Elan business, with the exception of its drug delivery businesses, now forms the Biopharmaceuticals business unit. The remaining businesses in Elan Enterprises, comprising principally drug delivery businesses, were amalgamated with the drug delivery business from Core Elan to form GS&O. Biopharmaceuticals engages in research, development and commercial activities and includes our autoimmune diseases franchise, our pain franchise, our neurodegenerative diseases franchise, and our commercial group for hospital products. GS&O focuses on product development and manufacturing to provide technology platforms that addresses the drug delivery challenges of the pharmaceutical industry. All prior period financial information has been reclassified to reflect the new basis of segmentation. Our total revenue of $464.0 million (2003: $762.1 million) was comprised of revenue from Biopharmaceuticals and GS&O of $300.9 million (2003: $612.6 million) and $163.1 million (2003: $149.5 million), respectively. Our operating loss of $390.0 million (2003: $935.1 million) was primarily comprised of operating losses incurred by Biopharmaceuticals and GS&O of $319.3 million (2003: $796.7 million) and $26.4 million (2003: $108.9 million), respectively.
Biopharmaceuticals’ revenue decreased 51% to $300.9 million in 2004 from $612.6 million in 2003, primarily due to product and business disposals. Biopharmaceuticals operating loss before exceptional items increased 13% to $316.9 million from $281.2 million in 2003 due to the disposal of products and businesses. Exceptional charges decreased to $2.4 million in 2004 from $515.5 million in 2003, primarily relating to the purchase of royalty rights from Pharma Marketing and asset impairments in 2003. GS&O revenue increased 9% to $163.1 million in 2004 from $149.5 million in 2003. GS&O operating loss before exceptional items decreased to $30.3 million in 2004 from $71.9 million in 2003, primarily due to the decrease in our expenses as a result of the business and product divestments in 2004. Exceptional gains decreased to $3.9 million in 2004 from $37.0 million in 2003, primarily reflecting the completion of the recovery plan in early 2004. For additional information regarding our reportable segments, please refer to Note 3 to the Consolidated Financial Statements. | EXCERPTS ON THIS PAGE:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
